RIPK1 and viral infectious disease: While the adverse effect of necroptosis inhibition is not clear, it is highly unlikely that inhibiting necroptosis by targeting RIPK1 will increase the susceptibility to viral infection because virus‐induced necroptosis occurs through the activation of RIPK3‐MLKL pathway, which is independent of RIPK1.